Q-linea AB (publ) announced that Stuart Gander succeeds Jonas Jarvius as CEO. Stuart Gander brings extensive experience from leading positions in the global healthcare industry, with a focus on diagnostics and medical technologies. Through his management consulting background, he has supported companies on a range of operational challenges with a focus on driving sustainable change and growth, based on building strong and motivated teams. Stuart Gander is a Canadian citizen, has previously been working 15 years in Sweden, is currently living in the USA but will relocate to Sweden within the next 18 months.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.18 SEK | -0.91% | -3.96% | -41.08% |
Apr. 26 | Q-Linea AB Receives FDA 510(k) Clearance for the ASTar® System | CI |
Mar. 13 | Q-linea AB Presents Strong ASTar Results At AMCLI | CI |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-41.08% | 24.02M | |
-42.33% | 2.95B | |
+19.36% | 1.88B | |
-1.05% | 1.63B | |
+33.96% | 1.34B | |
-16.83% | 959M | |
-21.96% | 888M | |
+7.07% | 842M | |
-27.02% | 623M | |
+10.85% | 513M |
- Stock Market
- Equities
- QLINEA Stock
- News Q-linea AB
- Q-linea AB Announces CEO Changes